



BUY

Holding steady...

ITC clocked in-line performance despite continued macro challenges. ITC's performance was in sync with other FMCG companies. ITC-Cig/ITC-FMCG growth was at 5/6% vs. HUL/Dabur/Colgate/Marico posted domestic growth of 4/6/4/-1% in 3QFY20. ITC's cig/FMCG performance was very much comparable to other FMCG cos for the past many quarters. Despite that, stock has de-rated over the last 12 months. We believe de-rating is unwarranted when the co is consistently showing quality earnings. We value ITC on SoTP basis (link to table) and arrive at a TP of Rs 360 (implied P/E of 25x). Maintain BUY.

HIGHLIGHTS OF THE QUARTER

- Cig. val/vol growth was 5/2% (10/5.5% in FY19, 10/7.5% in 3QFY19) was in-line with estimates. 8th consecutive quarter of positive volume growth vs. -4% CAGR over FY12-18. Volume growth moderated vs. FY19 owing to heavier base and impact from slowdown.
- Cig. EBIT grew by 6% (6.5% CAGR over FY15-19) vs. exp. of 8% growth. Cig. EBIT margins expanded by 60bps owing to (1) Gradual price hikes (~3%) and (2) Higher in-house manufacturing of capsule cig. Capsule cig is driving the growth for ITC and industry, it contributes 13% mix for ITC. Margin pressure was the key concern on the street in FY19 that has reversed in 9MFY20 (100bps expansion). We model 7% cig EBIT CAGR over FY20-22E.
- Non-cig business grew by 7% (est 9%. FMCG biz growth of

6% was in-line with our estimates FMCG posted EBITDA growth of 48% with EBITDA margin of 7.7%. Hotels/Agri/Paper revenue grew by 22/9/1% with EBIT growth of 45/7/1%. Non-cig EBIT grew by healthy 11% (11% average in the last 12 quarters, 7% over FY14-19).

GM was flat at 62% while employee/other expense grew by 6%/flat resulting in 7% EBITDA growth (11% in FY19 and 7% CAGR over FY15-18). APAT (at 25% tax rate) growth was 18% to Rs 37.8bn (est Rs 37.6bn).

STANCE

Stable taxes in FY19 accelerated cigarette volume growth to 5.5% vs. -5% CAGR during FY15-18. EBIT growth also accelerated to 9% as compared to 7% CAGR during FY15-18. Yet company could not enjoy re-rating as investors have flocked towards ITC's peers (HUL, Dabur and Britannia etc.). Rather cigarette business saw de-rating (>20% fall, based on assigning fair valuation to other segments) over the last 12-months.

We expect cig valuation will recover owing (1) Continuation of stable taxes, (2) EBIT margin expansion and (3) Pickup in rural market. We believe cigarette valuation will recover to its average of 18x EV/EBITDA (still lower than 25x for Colgate which is similar wrt market leadership, vol growth trajectory and pricing power). Other catalyst in the business is FMCG, better margin traction will also offer better value for ITC. We continue to believe that valuation discount will narrow down.

INDUSTRY	FMCG
CMP (as on 31 Jan 2020)	Rs 235
Target Price	Rs 360
Nifty	11,962
Sensex	40,723
KEY STOCK DATA	
Bloomberg	ITC IN
No. of Shares (mn)	12,292
MCap (Rs bn) / (\$ mn)	2,890/40,485
6m avg traded value (Rs mr	n) 3,347
STOCK PERFORMANCE (%)	
52 Week high / low	Rs 310/231

Solution Seek high / low Rs 310/231 3M 6M 12M Absolute (%) (8.7) (13.0) (15.6) Relative (%) (10.2) (21.6) (27.9)

SHAPEHOLDING DATTERN (%)

SHAKEHULDING PA	I I EKIN (%)	
	Sep-19	Dec-19
Promoters	0	0
FIs & Local MFs	42.45	42.58
FPIs	15.64	15.18
Public & Others	41.89	42.24
Pledged Shares	0.00	0.00
Source : BSE		

Financial Summary (Consolidated)

a	(/								
YE March (Rs mn)	3QFY20	3QFY19	YoY (%)	2QFY20	QoQ (%)	FY18	FY19	FY20E	FY21E	FY22E
Net Revenues	120,130	114,313	5.1	118,715	1.2	434,489	483,527	509,734	552,640	604,325
EBITDA	46,127	43,258	6.6	45,624	1.1	164,830	184,064	195,110	211,874	233,041
APAT	37,766	32,091	17.7	40,231	(6.1)	112,202	127,864	157,911	167,920	183,879
Diluted EPS (Rs)	3.1	2.6	17.6	3.3	(6.1)	9.2	10.4	12.9	13.7	15.0
P/E (x)						25.6	22.5	18.3	17.2	15.7
EV / EBITDA (x)						15.9	14.1	12.9	11.7	10.4
Core RoCE (%)						37.2	39.2	45.8	47.9	50.5

Source: Company, HDFC sec Inst Research

Naveen Trivedi

naveen.trivedi@hdfcsec.com +91-22-6171-7324

Aditya Sane

aditya.sane@hdfcsec.com +91-22-6171-7336



Net revenues grew by 5% (exp of 7%) as cig. revenue growth was steady at 5% despite

was steady at 5% despite consumption slowdown and floods

Cigarette volumes grew by ~2% (exp 2.5%; 7.5% in 3QFY19 and 3% in 2QFY20)

FMCG business grew by 4.2% driven by packaged foods and personal care products

EBITDA growth of 6.6% was below our exp of 9.2%

APAT (at 25% tax) growth of 17% was in line with our expectation

Quarterly Financials (Standalone)

Year to March (Rs mn)	3QFY20	3QFY19	YoY (%)	2QFY20	QoQ (%)	9MFY20	9MFY19	YoY (%)
Net Revenue	119,122	113,402	5.0	117,502	1.4	350,237	331,573	5.6
Other operating revenue	1,009	911	10.7	1,213	(16.9)	3,636	4,211	(13.6)
Total Revenue	120,130	114,313	5.1	118,715	1.2	353,873	335,784	5.4
Material Expenses	45,465	43,005	5.7	44,817	1.4	131,681	126,896	3.8
Employee Expenses	6,691	6,292	6.3	6,323	5.8	19,917	19,685	1.2
Other Operating Expenses	21,847	21,758	0.4	21,951	(0.5)	64,868	61,865	4.9
EBITDA	46,127	43,258	6.6	45,624	1.1	137,407	127,339	7.9
Depreciation	4,162	3,354	24.1	3,957	5.2	11,708	9,615	21.8
EBIT	41,965	39,904	5.2	41,667	0.7	125,700	117,723	6.8
Other Income	9,836	8,364	17.6	6,543	50.3	22,581	13,833	63.2
Interest Cost	124	56	121.7	133	(6.7)	410	265	55.0
PBT before exceptional	51,676	48,212	7.2	48,077	7.5	147,871	134,903	9.6
Exceptional	(1,321)	-	na	-	na	(1,321)	-	na
PBT	50,355	48,212	4.4	48,077	4.7	146,550	134,903	8.6
Tax	8,936	16,121	(44.6)	7,846	13.9	33,160	45,078	(26.4)
RPAT	41,419	32,091	29.1	40,231	3.0	113,390	89,824	26.2
Adjustment	(3,653)	-	na	-	na	(3,653)	-	na
APAT	37,766	32,091	17.7	40,231	(6.1)	109,737	89,824	22.2
EPS	3.1	2.6	17.6	3.3	(6.1)	14.2	11.7	22.2

% Of Net Revenue	3QFY20	3QFY19	YoY (bps)	2QFY20	QoQ (bps)	9MFY20	9MFY19	YoY (bps)
Material Cost	37.8	37.6	23	37.8	9	37.2	37.8	(58)
Employee Expenses	5.6	5.5	7	5.3	24	5.6	5.9	(23)
Other Expenses	18.2	19.0	(85)	18.5	(30)	18.3	18.4	(9)
EBITDA	38.4	37.8	56	38.4	(3)	38.8	37.9	91
Tax Rate	17.7	33.4	(1,569)	16.3	143	22.6	33.4	(1,079)
APAT	31.4	28.1	337	33.9	(245)	31.0	26.8	426

Cigarette business grew by 5% during the quarter with ~2% volume growth. Slightly below expectation performance

Non-cigarette portfolio continued to show healthy growth, registered 7% growth (9% average growth in the last 12 quarters)

Hotel biz sustaining robust growth and posted 22% growth, EBIT margin was strong at 16%

Paper revenue/EBIT growth was flat

Quarterly Segmental (Reported)

Year to March (Rs mn)	3QFY20	3QFY19	YoY (%)	2QFY20	QoQ (%)	9MFY20	9MFY19	YoY (%)
Segmental Revenues								
Cigarettes*	53,110	50,734	6.0	53,268	(0.3)	160,712	152,270	10.0
FMCG	33,123	32,010	6.5	32,883	0.7	96,607	92,314	12.6
Hotels	5,523	4,519	17.7	4,266	29.5	13,715	11,557	18.7
Agribusiness	20,947	19,246	19.3	26,475	(20.9)	83,534	72,956	14.5
Paperboards, Paper & Packaging	15,554	15,425	9.9	15,654	(0.6)	46,483	43,228	7.5
Total	128,257	121,933	8.7	132,547	(3.2)	401,052	372,325	7.7
Less: Inter-segment revenue	9,135	8,532	7.1	15,046	(39.3)	50,815	40,752	24.7
Total	119,122	113,402	5.0	117,501	1.4	350,236	331,573	5.6
Segmental EBIT								
Cigarettes	37,560	35,577	5.6	38,445	(2.3)	114,496	106,951	7.1
FMCG	1,076	767	40.4	905	19.0	2,761	1,852	49.1
Hotels	873	603	44.8	174	401.0	1,152	891	29.3
Agribusiness	2,134	1,988	7.4	2,494	(14.4)	6,658	6,294	5.8
Paperboards, Paper & Packaging	3,340	3,321	0.6	3,559	(6.2)	10,196	9,387	8.6
Total	44,983	42,256	6.5	45,577	(1.3)	135,262	125,375	7.9
Less:								
(a) Interest Cost & Bank Charges	124	56	121.7	133	(6.7)	410	586	(30.1)
(b) Other Un-allocable Expenses	(6,818)	(6,013)	13.4	(2,634)	158.9	(13,018)	(9,792)	32.9
РВТ	51,676	48,212	7.2	48,077	7.5	147,871	133,951	10.4
Capital Employed								
Cigarettes	34,935	36,336	(3.9)	37,544	(6.9)	34,935	36,336	(3.9)
FMCG	68,285	61,334	11.3	73,292	(6.8)	68,285	61,334	11.3
Hotels	56,915	52,330	8.8	55,985	1.7	56,915	52,330	8.8
Agribusiness	30,496	27,012	12.9	30,564	(0.2)	30,496	27,012	12.9
Paperboards, Paper & Packaging	61,368	61,345	0.0	60,808	0.9	61,368	61,345	0.0
Total	251,998	238,355	<i>5.7</i>	258,193	(2.4)	251,998	238,355	5.7
Unallocated corporate assets	357,467	302,890	18.0	312,364	14.4	357,467	302,890	18.0
Total capital employed	609,465	541,245	12.6	570,557	6.8	609,465	541,245	12.6

Source: Company, HDFC sec Inst Research *like-to-like revenue growth for FY19

Cig EBIT margins expanded owing to higher mix of capsule cigarettes

FMCG EBIT margin expansion was driven by enhanced scale, product mix enrichment and cost management initiatives notwithstanding higher investments in brand building and gestation costs of new categories


EBIT Margin (Reported)

Year to March (Rs mn)	3QFY20	3QFY19	YoY (bps)	2QFY20	QoQ (bps)	9MFY20	9MFY19	YoY (bps)
Cigarettes	70.7	70.1	60	72.2	(145)	71.2	73.2	(196)
FMCG	3.2	2.4	85	2.8	50	2.9	2.0	85
Hotels	15.8	13.3	247	4.1	1,173	8.4	7.7	69
Agribusiness	10.2	10.3	(14)	9.4	77	8.0	8.6	(66)
Paperboards, Paper & Packaging	21.5	21.5	(6)	22.7	(126)	21.9	21.7	22
Total	35.1	34.7	42	34.4	69	33.7	33.7	5

7th consecutive quarter of positive volume growth. We model 3.5% volume growth in FY21E/22E


Cigarette EBIT growth of 5.6% was below our estimate of 7.5%. We expect cig. EBIT to grow faster vs. revenue growth

Cigarette Value Growth




Source: Company, HDFC sec Inst Research

Cigarette Price Growth




Source: Company, HDFC sec Inst Research

Cigarette Volume Growth



Source: Company, HDFC sec Inst Research

Cigarette EBIT Growth






ITC's FMCG business growth in the recent quarters is at par with HUL


Hotel business is on a strong momentum driven by higher occupancy rates and ARR

FMCG Revenue Growth




Source: Company, HDFC sec Inst Research

Agri Revenue Growth




Source: Company, HDFC sec Inst Research

Hotel Revenue Growth



Source: Company, HDFC sec Inst Research

Paper Revenue Growth





FMCG segment mapping: ITC's addressable market offers a 13x opportunity headroom

Brand	Current Presence	Possible Extension	Brand Position	Mkt Position	Est. Market Size (Rs mn)	Est. ITC Revenue at Consumer level (Rs mn)	Key competitors
Food			•				
Aashirvaad	 - Wheat - Ghee - Spices - Instant mixes - Read-to-eat - Rice - Milk, Curd, Paneer - Salt 	 Pickles Grains (white flour, semolina, gram flour) Distribution expansion of new launches 	Mid	No. 1	150,000	45,000	- Pillsbury Atta (General Mills) - Silver Coin (Sanghvi Group) - Mother's Recipe
Sunfeast	BiscuitsCookiesCakeBeveragePasta	 Modern milk products Rusk/Bread Chocolates Oats Breakfast packaged food 	Mid to Premium	No.1 in premium biscuit segment	590,000	38,000	- Britannia, Parle, PriyaGold, Anmol
Bingo	Extruded snacksPotato Chips	- Healthy variants in salty snacks	Mid to Premium	No. 1	219,000	25,000	- Lays (Pepsi), Diamond (Prataap snacks), Too Yumm!, Haldiram
YiPPee	- Noodles - Pasta	- Oats	Mid	No. 2	153,000	11,000	- Maggi (Nestle), Top Ramen (Nissin)
Mint-o, Candyman, GumOn	- Confectionery	- More variants	Mid	Top 5	40,800	6,000	
B-Naturals	- Juices	- More variants - Healthy supplements	Mid to Premium	Emerging	20,000	4,800	- Real (Dabur), Tropicana (Pepsi)
Fabelle	- Chocolate	- Mass premium- Eventually, capture full portfolio	Super- premium	Emerging	80,000	150	- Cadburry (Mondelez), Nestle
Sunbean	- Coffee paste	Ready to drinkDistribution expansion	Premium	Emerging	15,000	100	- Nescafe (Nestle), Bru (HUL)
ITC Master Chef	Ready-to-eatFrozen foods (prawns)Fresh vegetables and fruitsSpicesMasala	- Variants in frozen foods - Distribution expansion	Mid to Premium	Emerging	4,000		



INSTITUTI	ONAL	RESEARCH
-----------	------	----------

Brand	Current Presence	Possible Extension	Brand Position	Mkt Position	Est. Market Size (Rs mn)	Est. ITC Revenue at Consumer level (Rs mn)	Key competitors
Personal Care	•	·	·	•			
Fiama	- Shower Gel - Soap Bar - Talc	- Shampoo - Shaving Cream - Talc - Face wash	Premium	No. 2	20,000	3,600	- Nivea: leader with 20% share (Beiersdorf Global) - Palmolive - Dove
Vivel Superia	- Soap Bar - Soap Bar	-More variants -More variants	Mid Mass	na na	200,000	6,000	- Lux, Lifebuoy, Dove, Pears, Hamam (HUL)- Godrej No 1, Cinthol (GCPL)- Santoor (Wipro)
Superia	- 30ар Баі	-iviole valiants	IVIGSS	11a			- Dettol (RB)
Superia	- Shampoo	-More variants	Mass	na	60,000		
Engage	- Deos - Perfume - Pocket Perfume	- Face Wash - Talc - More variants	Mid to Premium	No. 2	30,000	3,300	 Fogg: market leader with 17% (Vini) Wild Stone Nivea Park Avenue Axe
Essenza Di Wills	- Perfume	- Face cream - Moisturiser - Deo	Super- premium	Emerging	20,000	na	- Fogg (Vini) - Skinn (Titan) - Park Avenue (Raymond)
Savlon	- Anti-septic liquid - Soaps - Handwash - Hand sanitizer	 - Hand wash - Shaving Cream - Shower Gel - Disinfectant liquid 	Mid	No. 2	10,000	2,000	- Dettol (RB)
Charmis	- Cold cream	- Moisturiser	Mid	na	na	na	- Nivea (Beiersdorf Global) - Pond's (HUL)
Dermafique	- Anti-aging	- More variants	Premium	Emerging	na	na	- Olay (P&G) - Lakme (HUL) - Nivea (BG)
Shower to Shower	- Talc	- Shower Gel - Soap Bar - Talc	Mid	na	4,000	240	- Himalaya - Dermi Cool (RB) - Boroplus (Emami) - Nycil (Kraft Heinz)
Home Care							
Nimyle	Floor Cleaner	- Kitchen cleaner - More Variants	Mid	Emerging	100,000	na	- Lizol (RB) - Domex (HUL) - Mr. Muscle (SC Johnson)



Brand	Current Presence	Possible Extension	Brand Position	Mkt Position	Est. Market Size (Rs mn)	Est. ITC Revenue at Consumer level (Rs mn)	Key competitors
Others							
Classmate Paperkraft	NotebooksPenPencilGeometric boxArt instruments	- More variants - Office stationery	Premium	No. 2	100,000	10,000	- Navneet - Luxor - BILT (Balrampur)
Wills	Life Style	- Restructure business	Premium	na	na	7,185	- All leading mens formal wear brands
Aim Ship Home Lites	Safety Matches	 Cigarette and gas stove lighters 	Mid	No. 1	10,000	2,422	- Largely unorganised




ITC's FMCG business is dominated by packaged foods (77% revenue mix vs. 71% in FY14)

Gross margins for FMCG business is at par with peers (40-45%). However, mid-single digit EBITDAM is owing to (1) Higher upfront brand investments and (2) Losses in retail business


EBIT margins are steadily expanding as brands gain critical scale and co has restructured retail biz

FMCG Revenue mix: Packaged food dominates




Source: Company, HDFC sec Inst Research

FMCG revenue product mix




Source: Company, HDFC sec Inst Research

Top brands in FMCG (size at consumer level)



Source: Company, HDFC sec Inst Research

FMCG EBIT margins: ~9% swing over FY11-19





Assumptions

Particulars	FY16	FY17	FY18	FY19	FY20E	FY21E	FY22E
Cigarette							
Revenue Gr (%)	6.2	(40.5)	4.9	10.3	5.5	6.6	6.6
Volume Gr (%)	(8.8)	1.4	(3.0)	5.6	2.6	3.5	3.5
Cig. Price Gr (%)	15.0	(41.8)	7.9	4.6	2.9	3.1	3.1
EBIT Gr (%)	5.0	6.5	6.6	9.1	6.9	7.2	7.0
FMCG							
Revenue Gr (%)	7.7	8.0	11.3	12.6	5.2	8.8	12.3
EBIT Margin (%)	0.7	0.3	1.4	2.5	3.2	4.1	4.6
Hotel							
Revenue Gr (%)	11.5	1.6	5.6	17.3	11.7	10.1	10.5
EBIT Gr (%)	13.4	99.3	26.0	27.1	23.9	16.4	14.4
EBIT Margin (%)	4.3	8.3	9.9	10.7	12.5	13.0	13.0
Agri business							
Revenue Gr (%)	0.2	(5.8)	(15.0)	16.9	10.7	10.4	10.4
EBIT Gr (%)	2.8	(2.6)	(6.3)	(8.5)	7.0	12.1	12.1
EBIT Margin (%)	12.5	11.0	10.5	8.3	7.8	7.9	8.1
Paper & Paper boards							
Revenue Gr (%)	5.9	(0.8)	(0.7)	10.1	11.5	11.6	11.7
EBIT Gr (%)	(1.5)	6.4	7.9	18.9	9.6	13.4	12.3
EBIT Margin (%)	17.0	18.0	19.9	21.1	21.4	21.9	22.1
Gross Margin (%)	65.4	62.5	63.5	64.0	64.7	65.1	65.3
Employee (% of sales)	8.8	8.5	8.7	8.6	9.0	9.0	9.1
ASP (% of sales)	2.5	1.9	2.1	2.1	2.1	2.2	2.2
Distribution (% of sales)	2.2	2.0	2.1	2.4	2.3	2.4	2.4
Other Expenses (% of sales)	15.0	14.1	12.8	12.8	13.1	13.1	13.1
EBITDA Margin (%)	36.9	36.1	37.9	38.1	38.3	38.3	38.6
Tax Rate (%)	36.1	34.6	34.0	33.0	24.0	25.2	25.2



Based on our assumptions, implied 5 year historical valuations for ITC's cig business ranges between 15-20x EV/EBITDA

We believe FMCG business has witnessed a re-rating over the years owing to higher scale and margin expansion

Re-rating in hotels is led by favourable industry dynamics (higher ARR and occupancy rate)

Re-rating in paper is led by recovery in volume growth in

FMCG industry. Co has also expanded margins owing to richer product mix (focus on value added)

Valuation table

Segments (Rs bn)		FY15	FY16	FY17	FY18	FY19
Cigarette	EBITDA	103	115	121	128	136
	EV/EBITDA (x)	20.1	15.2	16.7	16.6	16.3
	EV (1Yr Fwd)	2,072	1,748	2,019	2,123	2,215
	Per share	185	160	183	194	203
	Rev Gr (%)	9%	4%	5%	5%	10%
	Vol Gr (%)	-8.8%	-8.8%	1.4%	-3.0%	5.6%
	EBIT Gr (%)	12%	5%	6%	7%	9%
FMCG	Revenue	90	97	105	113	125
	EV/Revenue (x)	4.1	4.3	4.5	4.8	5.0
	EV (1Yr Fwd)	400	454	514	595	657
	Per share	33	38	42	49	54
	Rev Gr (%)	11%	8%	8%	11%	13%
	EBIT Marg (%)	0.4%	0.7%	0.3%	1.4%	2.5%
	EBIT Gr (%)	56%	107%	-60%	484%	135%
Hotel	EBITDA	3	2	2	3	3
	EV/EBITDA (x)	13.7	15.0	16.5	18.2	20.0
	EV (1Yr Fwd)	33	34	47	62	79
	Per share	3	3	4	5	6
Agri	EBITDA	9	10	10	10	9
	EV/EBITDA (x)	8	8	8	8	8
	EV (1Yr Fwd)	76	78	78	74	68
	Per share	6	6	6	6	6
Paper	EBITDA	11	12	12	12	14
	EV/EBITDA (x)	8.2	8.6	9.1	9.5	10.0
	EV (1Yr Fwd)	96	100	113	130	159
	Per share	8	8	9	11	13
EV		2,677	2,415	2,771	2,985	3,179
Cash+Invest		148	180	205	250	278
Mkt cap		2,825	2,595	2,976	3,234	3,457
Shares		12	12	12	12	12
CMP (Avg)		235	215	245	265	282



SOTP Valuation

Segments	Criteria	Value
Cigarette	EBITDA (Rs mn)	167
	EV/EBITDA (x)	18
	EV (Rs mn)	3,010
FMCG	Revenue (Rs mn)	156
	EV/Revenue (x)	5
	EV (Rs mn)	780
Hotel	EBITDA (Rs mn)	5
	EV/EBITDA (x)	20
	EV (Rs mn)	101
Agri	EBITDA (Rs mn)	10
	EV/EBITDA (x)	8
	EV (Rs mn)	80
Paper	EBITDA (Rs mn)	19
	EV/EBITDA (x)	10
	EV (Rs mn)	191
Total EV		4,161
Cash+Investment		360
Mkt Cap		4,521
ТР		360



Changes In Estimates

Fatimata Change		FY20E			FY21E			FY22E	
Estimate Change	New	Old	Change (%)	New	Old	Change (%)	New	Old	Change (%)
Revenue	509,734	512,127	(0.5)	552,640	558,835	(1.1)	604,325	613,439	(1.5)
EBITDA	195,110	196,409	(0.7)	211,874	215,247	(1.6)	233,041	238,021	(2.1)
APAT	157,911	158,072	(0.1)	167,920	169,655	(1.0)	183,879	186,147	(1.2)
EPS	12.9	12.9	(0.1)	13.7	13.8	(1.0)	15.0	15.2	(1.2)

Peer Set Comparison


	MCap	СМР	ТР			EPS (Rs) P/E (x) EV/		P/E (x)		P/E (x) EV/EBITD		EBITDA	(x)	Cor	e RoCE	(%)
Company	(Rs bn)	(Rs)	Reco.	(Rs)	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
HUL	4,339	2,034	NEU	1,988	33.5	40.7	45.3	60.8	50.0	44.9	42.7	35.4	31.7	36.6	26.7	30.4
ITC	2,890	235	BUY	360	12.9	13.7	15.0	18.3	17.2	15.7	12.9	11.7	10.4	45.8	47.9	50.5
Nestle	1,487	15,548	NR	13,842	233.3	277.4	317.7	66.6	56.1	48.9	46.0	39.4	34.2	112.2	128.8	162.2
Dabur	873	496	BUY	510	8.9	11.3	13.1	55.6	43.7	37.8	43.2	36.5	31.2	52.4	59.3	65.5
Britannia	768	3,201	BUY	3,678	58.9	70.8	85.4	54.3	45.2	37.5	39.7	32.7	27.1	42.7	48.7	55.3
Marico	407	315	NEU	350	8.2	9.1	10.6	38.5	34.6	29.8	27.2	24.9	22.0	44.6	48.3	54.1
United Spirits	450	619	BUY	759	12.3	16.1	19.2	50.2	38.6	32.3	29.1	24.7	21.1	18.3	21.7	23.8
Colgate	362	1,329	NEU	1,392	30.4	35.5	41.3	43.7	37.4	32.2	27.8	24.3	21.1	70.8	81.0	94.9
Jubilant Food	249	1,890	BUY	2,178	31.6	40.0	49.8	59.9	47.2	38.0	36.9	29.2	23.7	33.5	24.2	31.7
Emami	138	295	BUY	463	12.5	14.1	15.9	23.5	21.0	18.5	17.0	15.2	13.4	25.6	30.6	38.0
Radico Khaitan	53	396	BUY	527	16.4	21.4	24.8	24.1	18.6	16.0	14.6	11.8	10.1	15.1	15.5	16.7



High rates of tax on cigarettes provide attractive tax arbitrage opportunities to unscrupulous players, fanning the growth of illegal cigarette trade in the country


The legitimate cigarette industry has declined steadily since 2010-11 at a compound annual rate of 4.8% p.a., illegal cigarette volumes in contrast have grown at about 5% p.a.

India's Tobacco Consumption Tobacco consumption share




Source: Company, HDFC sec Inst Research

Per capita consumption of Tobacco in India – Per annum




Source: Company, HDFC sec Inst Research

Tax revenue share



Source: Company, HDFC sec Inst Research

Affordability (% of per capita GDP required to purchase 100 packs of 20 cigarettes of most sold brand





Income Statement

(Rs mn)	FY18	FY19	FY20E	FY21E	FY22E
Net Revenues	434,489	483,527	509,734	552,640	604,325
Growth (%)	4.5	11.3	5.4	8.4	9.4
Material Expenses	158,555	174,203	179,936	192,871	209,701
Employee Expense	37,609	41,779	45,698	50,010	54,753
ASP Expense	9,041	9,946	10,704	12,158	13,295
Distribution Expense	9,041	11,765	11,724	13,263	14,504
Other Expenses	55,414	61,770	66,561	72,463	79,031
EBITDA	164,830	184,064	195,110	211,874	233,041
EBITDA Growth (%)	6.8	11.7	6.0	8.6	10.0
EBITDA Margin	37.9	38.1	38.3	38.3	38.6
Depreciation	12,363	13,966	15,359	16,914	18,609
EBIT	152,467	170,098	179,751	194,960	214,432
Other Income (Including EO)	18,319	21,738	28,085	29,476	31,305
Interest	899	454	236	241	246
PBT	174,016	191,381	207,600	224,195	245,492
Total Tax	59,164	63,139	49,824	56,430	61,790
RPAT	114,927	128,359	157,911	167,920	183,879
Exceptional Gain/(loss)	2,725	495	-	-	-
Adjusted PAT	112,202	127,864	157,911	167,920	183,879
APAT Growth (%)	7.1	14.0	23.5	6.3	9.5
Adjusted EPS (Rs)	9.19	10.43	12.88	13.70	15.00
EPS Growth (%)	6.6	13.5	23.5	6.3	9.5

Source: Company, HDFC sec Inst Research

Balance Sheet

(Rs mn)	FY18	FY19	FY20E	FY21E	FY22E
SOURCES OF FUNDS	L110	F113	FIZUE	FIZIE	FIZZE
	12 204	12.250	12 250	12 250	12.250
Share Capital - Equity	12,204	12,259	12,259	12,259	12,259
Reserves	512,897	565,114	638,188	701,336	773,803
Total Shareholders' Funds	525,101	577,372	650,447	713,594	786,061
Minority Interest	3,345	3,435	3,300	3,145	2,967
Long Term Debt	115	82	82	82	82
Short Term Debt	174	19	20	23	25
Total Debt	289	100	102	104	106
Net Deferred Taxes	18,749	19,927	21,248	22,674	24,215
Other non current liabilities	2,596	2,484	2,484	2,484	2,484
TOTAL SOURCES OF FUNDS	550,080	603,318	677,580	742,002	815,833
APPLICATION OF FUNDS					
Net Block	163,907	191,530	207,481	236,567	248,658
CWIP	77,353	63,618	55,366	48,764	43,483
Goodwill	2,314	2,314	2,314	2,314	2,314
LT Loans & Advances	21,014	16,960	18,349	19,852	21,481
Total Non-current Assets	264,587	274,422	283,510	307,497	315,935
Inventories	74,951	79,440	80,819	84,999	90,476
Debtors	26,823	40,353	30,074	32,606	35,655
Other Expenses	26,523	30,852	32,394	34,014	35,715
Cash & Equivalents	249,525	278,353	359,556	401,690	468,215
Total Current Assets	377,821	428,997	502,844	553,309	630,061
Creditors	34,962	35,096	37,512	40,669	44,473
Other Current Liabilities & Provns	57,367	65,006	71,261	78,135	85,690
Total Current Liabilities	92,328	100,101	108,773	118,805	130,163
Net Current Assets	285,493	328,896	394,070	434,504	499,898
TOTAL APPLICATION OF FUNDS	550,080	603,318	677,580	742,002	815,833



Cash Flow Statement


Source: Company, HDFC sec Inst Research

Key Ratios

Key Ratios					
	FY18	FY19	FY20E	FY21E	FY22E
PROFITABILITY (%)					
GPM	63.5	64.0	64.7	65.1	65.3
EBITDA Margin	37.9	38.1	38.3	38.3	38.6
EBIT Margin	35.1	35.2	35.3	35.3	35.5
APAT Margin	25.8	26.4	31.0	30.4	30.4
RoE	22.7	23.2	25.7	24.6	24.5
RoIC (or Core RoCE)	37.2	39.2	45.8	47.9	50.5
RoCE	22.6	23.1	25.6	24.5	24.4
EFFICIENCY					
Tax Rate (%)	34.0	33.0	24.0	25.2	25.2
Fixed Asset Turnover (x)	0.6	0.7	0.7	0.7	0.7
Inventory (days)	63.0	60.0	57.9	56.1	54.6
Debtors (days)	22.5	30.5	21.5	21.5	21.5
Other Current Assets (days)	22.3	23.3	23.2	22.5	21.6
Payables (days)	29.4	26.5	26.9	26.9	26.9
Other Current Liab & Provns (days)	48.2	49.1	51.0	51.6	51.8
Cash Conversion Cycle (days)	30.2	38.2	24.7	21.7	19.1
Net D/E (x)	(0.5)	(0.5)	(0.6)	(0.6)	(0.6)
Interest Coverage (x)	169.6	374.5	761.1	809.9	872.5
PER SHARE DATA (Rs)					
EPS	9.2	10.4	12.9	13.7	15.0
CEPS	10.2	11.6	14.1	15.1	16.5
Dividend	5.2	5.8	7.1	7.6	8.3
Book Value	43.0	47.1	53.1	58.2	64.1
VALUATION					
P/E (x)	25.6	22.5	18.3	17.2	15.7
P/BV (x)	5.5	5.0	4.4	4.0	3.7
EV/EBITDA (x)	15.9	14.1	12.9	11.7	10.4
EV/Revenues (x)	6.0	5.4	4.9	4.5	4.0
OCF/EV (%)	5.0	4.6	6.9	6.9	7.7
FCF/EV (%)	3.9	3.5	6.0	5.3	6.7
FCFE/Mkt Cap (%)	3.6	3.2	5.3	4.6	5.6
Dividend Yield (%)	2.2	2.4	3.0	3.2	3.5



RECOMMENDATION HISTORY



Date	CMP	Reco	Target
9-Jan-19	284	BUY	383
23-Jan-19	278	BUY	383
10-Apr-19	296	BUY	394
14-May-19	289	BUY	398
9-Jul-19	273	BUY	397
5-Aug-19	265	BUY	362
22-Sep-19	238	BUY	365
11-Oct-19	238	BUY	370
25-Oct-19	249	BUY	368
9-Jan-20	236	BUY	366
1-Feb-20	235	BUY	360

Rating Definitions

BUY : Where the stock is expected to deliver more than 10% returns over the next 12 month period NEUTRAL : Where the stock is expected to deliver (-)10% to 10% returns over the next 12 month period : Where the stock is expected to deliver less than (-)10% returns over the next 12 month period

HDFC securities Institutional Equities

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013

Board: +91-22-6171 7330 www.hdfcsec.com



Disclosure:

We, **Naveen Trivedi**, **MBA & Aditya Sane**, **CA**, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does not have any material conflict of interest.

Any holding in stock -No

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from t date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: HDF 2806925/HDF C000222657; SEBI Research Analyst Reg. No.: INH000002475: SEBI Investment Adviser Reg. No.: INA000011538: CIN - U67120MH2000PLC152193

Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.